{
  "id": "5a87f44061bb38fb2400000f",
  "type": "factoid",
  "question": "Which disorder has been approved for treatment with Alk inhibitors?",
  "ideal_answer": "Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28669346",
    "http://www.ncbi.nlm.nih.gov/pubmed/27707887",
    "http://www.ncbi.nlm.nih.gov/pubmed/27865624",
    "http://www.ncbi.nlm.nih.gov/pubmed/28054318",
    "http://www.ncbi.nlm.nih.gov/pubmed/27545320",
    "http://www.ncbi.nlm.nih.gov/pubmed/27498387",
    "http://www.ncbi.nlm.nih.gov/pubmed/28050598"
  ],
  "snippets": [
    {
      "text": "Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, is approved for treatment of patients with ALK+ non-small cell lung cancer who have progressed, on or are intolerant to, crizotinib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27545320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Ceritinib is a highly selective ALK inhibitor and shows promising efficacy in non-small cell lung cancers (NSCLC) harboring the ALK gene rearrangement. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27707887",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dramatic and often prolonged responses are seen in patients withALKalterations when treated with ALK inhibitors. Three of these-crizotinib, ceritinib, and alectinib-are now FDA approved for the treatment of metastatic NSCLC positive forALKfusions",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28050598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, novel ALKis exhibit good antitumor efficacy for brain metastases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27865624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction Crizotinib was approved to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by the Food and Drug Administration in 2011.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Crizotinib treatment would be a favorable treatment option for patients with ALK-positive NSCLC. ALK inhibitors may have future potential applications in other cancers driven by ALK or c-MET gene mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669346",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ALK-positive lung cancer"
}